Massey Quick Simon & CO. LLC Purchases 786 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Share on StockTwits

Massey Quick Simon & CO. LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 40.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,726 shares of the biopharmaceutical company’s stock after purchasing an additional 786 shares during the period. Massey Quick Simon & CO. LLC’s holdings in Gilead Sciences were worth $173,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Gilead Sciences by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 102,062,449 shares of the biopharmaceutical company’s stock valued at $6,895,339,000 after acquiring an additional 715,569 shares during the period. Invesco Ltd. increased its holdings in shares of Gilead Sciences by 17.5% in the 2nd quarter. Invesco Ltd. now owns 22,975,310 shares of the biopharmaceutical company’s stock valued at $1,552,213,000 after acquiring an additional 3,418,193 shares during the period. Northern Trust Corp increased its holdings in shares of Gilead Sciences by 2.1% in the 2nd quarter. Northern Trust Corp now owns 17,187,741 shares of the biopharmaceutical company’s stock valued at $1,161,204,000 after acquiring an additional 347,443 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Gilead Sciences by 56.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,740,248 shares of the biopharmaceutical company’s stock valued at $860,731,000 after acquiring an additional 4,620,000 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Gilead Sciences by 0.8% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 12,109,533 shares of the biopharmaceutical company’s stock valued at $818,120,000 after acquiring an additional 90,251 shares during the period. 79.67% of the stock is owned by institutional investors and hedge funds.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 608 shares of Gilead Sciences stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $64.35, for a total transaction of $39,124.80. Following the completion of the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at approximately $1,750,191.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Olsen Per Wold sold 4,908 shares of Gilead Sciences stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $63.91, for a total value of $313,670.28. Following the sale, the director now directly owns 102,762 shares of the company’s stock, valued at approximately $6,567,519.42. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,716 shares of company stock worth $821,299. 0.20% of the stock is owned by company insiders.

GILD stock traded up $0.29 on Wednesday, hitting $65.59. 1,807,810 shares of the company’s stock were exchanged, compared to its average volume of 5,795,885. Gilead Sciences, Inc. has a 12-month low of $60.32 and a 12-month high of $76.44. The firm has a 50 day moving average price of $64.23 and a two-hundred day moving average price of $65.36. The company has a debt-to-equity ratio of 1.13, a quick ratio of 3.67 and a current ratio of 3.76. The stock has a market cap of $83.05 billion, a P/E ratio of 10.66, a price-to-earnings-growth ratio of 3.03 and a beta of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.14. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.54 billion. During the same period in the previous year, the business earned $1.91 EPS. The firm’s revenue for the quarter was down 2.8% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences, Inc. will post 6.67 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were paid a dividend of $0.63 per share. The ex-dividend date was Thursday, September 12th. This represents a $2.52 annualized dividend and a yield of 3.84%. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.

A number of research analysts have recently issued reports on the company. Credit Suisse Group cut their price target on Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating on the stock in a report on Wednesday, July 31st. BMO Capital Markets set a $82.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, July 31st. Raymond James set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Friday, August 23rd. Citigroup set a $78.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, July 31st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $82.24.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: How to Use a Moving Average for Trading 

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.